AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01967797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5As Team Intervention
Description: The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
Study NCT02250131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perfusion targeted at oxygen delivery
Description: Flow on cardiopulmonary bypass based on a target oxygen delivery > 280 mL/min/m2
Study NCT00617097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: paracervical block with lidocaine
Study NCT00617097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac and lidocaine
Description: paracervical block with ketorolac and lidocaine
Study NCT03060993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Patients will be administered cannabis (THC/CBD) in vaporized form.
Study NCT03060993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
Study NCT02575872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in physical activity behavioral intervention
Study NCT05195086 — intervention group
Intervention type: DRUG
Intervention: endoxan
Description: Immunosuppressant
Study NCT05195086 — intervention group
Intervention type: DRUG
Intervention: cellcept
Description: Immunosuppressant
Study NCT01389726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
Study NCT01389726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
Study NCT01389726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial-Informational support
Description: Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
Study NCT02383186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermal Suturing Only Wound Closure
Description: The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
Study NCT02383186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Layered Cutaneous Wound Closure
Description: The side assigned to layered closure is closed with 5-0 fast acting gut.
Study NCT01151384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LE-DT
Description: Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
Study NCT04993248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialog Circle
Description: The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator.
Study NCT01395966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF277
Description: Ear drops
Study NCT01395966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF289 plus DF277
Description: Ear drops
Study NCT04834258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking and respiratory training
Description: Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged
Study NCT04834258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
Study NCT02515149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care CD4 device (Alere PIMA)
Description: for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
Study NCT01325727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief computerized feedback
Description: Brief computerized feedback
Study NCT00068315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00068315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00068315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT02622295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session electrically induced exercise
Description: A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
Study NCT02622295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrically-induced exercise training
Description: Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
Study NCT01737983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.
Study NCT01737983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
Study NCT02483858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR 309
Description: Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
Study NCT04033614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fasciotens-Abdomen
Description: The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
Study NCT02688829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin target-eluting Coronary Stent System
Description: Implantation of the rapamycin-eluting coronary stent system
Study NCT01009970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 day 1
Study NCT04176757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 study drug to be administered orally daily
Study NCT01009970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 day 2
Study NCT02034383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Controlled diet for 3 weeks with 0 servings/day of almonds.
Study NCT02034383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Almonds
Description: Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
Study NCT02034383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roasted Whole Almonds
Description: Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
Study NCT02034383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diced Almonds
Description: Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
Study NCT02034383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Butter
Description: Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
Study NCT03564314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORT AKI Clinical Decision Support
Description: Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
Study NCT01325727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resources only (control)
Description: Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
Study NCT02976324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external diaphragmatic pacemaker group
Description: 9 counts per minute, with stimulate frequency 40 Hz
Study NCT01687426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 0.025%
Description: 1 drop in each eye daily four times a day for 14 days
Study NCT01009970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/m2 (max 2 mg) day 2
Study NCT01009970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2 day 2-6
Study NCT01009970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 day 2
Study NCT03164252 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Grupo I- Lower laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
Study NCT03164252 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Grupo I- Lower laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
Study NCT03164252 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Grupo II- Greater laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
Study NCT03164252 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Grupo II- Greater laser fluency
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
Study NCT03164252 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Grupo III- Laser sham
Description: The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
Study NCT01238471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: 2 mg per kg per day divided in 3 doses for 2-4 weeks
Study NCT01238471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sucrose 5%
Description: 2 ml per Kg per day divided in 3 doses for 2-4 weeks
Study NCT00476905 — intervention group
Intervention type: DEVICE
Intervention: Spectral Diagnosis Probe
Description: The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
Study NCT04180579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAXMAN Scalp Cooler
Description: Scalp cooling will occur with each dose of chemotherapy.
Study NCT03526406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CP9700
Description: 400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
Study NCT03077711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
Study NCT03077711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methenamine hippurate
Description: antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
Study NCT02332876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02332876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT00650364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl Tablets 5 mg
Description: 5mg, single dose fasting
Study NCT00650364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAmatine® Tablets 5 mg
Description: 5mg, single dose fasting
Study NCT03526406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
Study NCT01841021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
Study NCT00644514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin - lipopolysaccharide (LPS)
Description: Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
Study NCT04189302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft harvest using KPM blade
Description: after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
Study NCT04189302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft harvest using 15 C blade
Description: after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
Study NCT00507884 — intervention group
Intervention type: PROCEDURE
Intervention: 3 Tesla MRI Scan
Description: MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
Study NCT01412736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4563
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
Study NCT01412736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
Study NCT04025164 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
Study NCT04025164 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fractionated Radiotherapy
Description: daily fractions, 2 Gy per fraction, five fractions per week
Study NCT00104741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Study NCT00104741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Study NCT00104741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00104741 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT01219790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external radiotherapy
Description: All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
Study NCT01219790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acide zoledronic
Description: The administration of zoledronic acid as defined under the Authorisation on the Market.
Study NCT01831011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mildronate injection
Study NCT01831011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinepazide maleate injection
Study NCT00075855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic testosterone
Study NCT00075855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Study NCT00763295 — intervention group
Intervention type: OTHER
Intervention: T-Spot.TB test
Description: diagnostic test
Study NCT01831011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Study NCT01831011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study NCT01687426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brimonidine Tartrate 0.025%
Description: 1 drop in each eye daily four times a day for 14 days
Study NCT01687426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye daily four times a day for 14 days
Study NCT01687426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye daily four times a day for 14 days